#1 Clinical Trials Search in Europe

Omalizumab

Omalizumab, also known by the brand name Xolair, is a medication that has been the subject of numerous clinical trials for various allergic and inflammatory conditions. These trials have explored its efficacy and safety in treating conditions such as asthma, chronic spontaneous urticaria (hives), and even in preventing allergic reactions during immunotherapy. This article summarizes key findings from recent clinical trials investigating the use of omalizumab in different patient populations and conditions.

Table of Contents

What is Omalizumab?

Omalizumab, also known by its brand name Xolair, is a medication used to treat certain allergic and inflammatory conditions[1]. It belongs to a class of drugs called monoclonal antibodies, which are laboratory-produced molecules designed to serve as substitute antibodies that can restore, enhance, or mimic the immune system’s attack on specific cells[1]. Omalizumab specifically targets and neutralizes a type of antibody called Immunoglobulin E (IgE), which plays a crucial role in allergic reactions[1].

Conditions Treated with Omalizumab

Omalizumab is primarily used to treat the following conditions:

  • Allergic Asthma: It is used for patients with moderate to severe persistent allergic asthma that is not well-controlled with inhaled corticosteroids[2].
  • Chronic Spontaneous Urticaria (CSU): Also known as chronic idiopathic urticaria, this condition causes recurring hives and itching. Omalizumab is used for patients who don’t respond well to standard antihistamine treatments[3].
  • Chronic Rhinosinusitis with Nasal Polyps: While not explicitly mentioned in the provided trials, this is another FDA-approved use for omalizumab.

How Omalizumab Works

Omalizumab works by binding to and neutralizing IgE antibodies in the blood[1]. In allergic conditions, IgE triggers the release of chemicals that cause inflammation and allergy symptoms. By reducing the amount of free IgE, omalizumab helps prevent allergic reactions and reduces inflammation in the airways and skin[4].

In the case of asthma, omalizumab can help reduce airway inflammation and hypersensitivity (overreaction of the airways to triggers)[1]. For chronic urticaria, it helps reduce the occurrence of hives and itching by interfering with the allergic process[3].

How Omalizumab is Administered

Omalizumab is typically administered as a subcutaneous (under the skin) injection[3]. The dosage and frequency of injections can vary depending on the condition being treated, the patient’s body weight, and their initial IgE levels[2]. Common dosing schedules include:

  • Every 2 or 4 weeks for asthma, with doses ranging from 150 to 375 mg[2]
  • 300 mg every 4 weeks for chronic spontaneous urticaria[3]

The medication is usually administered by a healthcare professional in a clinical setting where the patient can be monitored for potential allergic reactions[3].

Effectiveness of Omalizumab

Clinical trials have shown omalizumab to be effective in treating its approved conditions:

  • For Asthma: Omalizumab has been shown to reduce asthma exacerbations (sudden worsening of symptoms) and improve symptoms in patients with moderate to severe allergic asthma[5]. It may also help reduce the need for inhaled corticosteroids[6].
  • For Chronic Spontaneous Urticaria: Studies have shown that omalizumab can significantly reduce itching and the number of hives in patients who haven’t responded well to antihistamines[3]. Many patients achieve well-controlled urticaria (measured by a score called UAS7) after 12 weeks of treatment[3].

Potential Side Effects

While omalizumab is generally well-tolerated, like all medications, it can cause side effects. Common side effects may include:

  • Injection site reactions (redness, swelling, itching)[5]
  • Headache
  • Fatigue
  • Nausea

In rare cases, more serious allergic reactions can occur. Patients are usually monitored after receiving injections, especially in the beginning of treatment[3].

Ongoing Research and Future Applications

Researchers continue to study omalizumab for potential new applications and to better understand its effects:

  • Prevention of Allergic Reactions to Immunotherapy: Studies are exploring whether omalizumab can improve the tolerability of allergen immunotherapy (allergy shots) in patients with allergic asthma[2].
  • Understanding Mechanism of Action: Researchers are investigating how omalizumab affects various cells involved in allergic reactions, such as basophils (a type of white blood cell)[7].
  • Potential Use in Other Conditions: Some research is exploring the use of omalizumab in preventing hypersensitivity reactions to certain chemotherapy drugs[8].

These ongoing studies may lead to new applications or improved treatment strategies with omalizumab in the future.

Aspect Details
Conditions Studied Allergic asthma, Chronic spontaneous urticaria, Oxaliplatin-induced hypersensitivity reactions
Key Outcomes Measured Asthma exacerbations, Urticaria activity score, Airway hyperresponsiveness, Tolerability of immunotherapy
Dosing Regimens 150-375 mg subcutaneously every 2-4 weeks, dosage based on weight and baseline IgE levels
Patient Populations Adults and children with moderate to severe allergic asthma, patients with chronic urticaria, cancer patients with oxaliplatin sensitivity
Safety Assessments Adverse events, serious adverse events, injection site reactions
Efficacy Markers Reduction in IgE levels, improvement in symptom scores, decreased use of rescue medications
Study Designs Randomized controlled trials, open-label studies, retrospective database analyses

FAQ

  • What is omalizumab and how does it work? Omalizumab is a monoclonal antibody that targets and neutralizes immunoglobulin E (IgE), a key molecule in allergic reactions. By reducing free IgE levels in the body, it helps prevent allergic symptoms and inflammation in conditions like asthma and chronic hives.
  • What conditions has omalizumab been studied for in clinical trials? Clinical trials have investigated omalizumab for various conditions, including moderate to severe allergic asthma, chronic spontaneous urticaria (chronic hives), and for improving tolerability of allergen immunotherapy in asthma patients.
  • How is omalizumab typically administered? Omalizumab is usually administered as a subcutaneous injection. The dosage and frequency can vary depending on the condition being treated, the patient's weight, and their baseline IgE levels. In many trials, it was given every 2 or 4 weeks.
  • What are some potential benefits of omalizumab treatment? Clinical trials have shown that omalizumab can reduce asthma exacerbations, improve symptoms in chronic urticaria, decrease the need for other medications like corticosteroids, and potentially improve the safety and efficacy of allergen immunotherapy.
  • Are there any side effects associated with omalizumab? While omalizumab is generally well-tolerated, clinical trials monitored for potential side effects. Common side effects can include injection site reactions, headaches, and upper respiratory tract infections. Serious allergic reactions are rare but possible.

Ongoing Clinical Trials on Omalizumab

  • Study on Stopping Omalizumab in Patients with Well-Controlled Severe Allergic Asthma After 3 Years of Treatment

    Recruiting

    3 1 1 1
    Investigated drugs:
    France

  • Omalizumab monotherapy for patients with vegetable (plant‑based food) allergy due to LTP and profilin sensitization

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • A study to evaluate the safety and effectiveness of omalizumab in adults with episodic migraine

    Not yet recruiting

    2 1 1 1
    Investigated drugs:
    Norway

  • Study on Adjusting Omalizumab Dosage for Patients with Severe Allergic Asthma

    Not yet recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on the Safety and Effectiveness of Low-Dose Oral Immunotherapy with Omalizumab for Children with Severe Cow’s Milk Allergy

    Not yet recruiting

    2 1 1 1
    Investigated diseases:
    Investigated drugs:
    Spain

  • Study on Omalizumab and Mepolizumab for Patients with Severe Allergic and Eosinophilic Asthma

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium France

  • Study on the Effects of Omalizumab on Carotid Artery Stenosis in Patients Undergoing Carotid Endarterectomy

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    The Netherlands

  • Study Comparing BP11 and Omalizumab for Patients with Chronic Spontaneous Urticaria Resistant to H1 Antihistamines

    Not recruiting

    3 1 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Hungary Latvia Lithuania Poland Slovakia

  • Study on Extending Omalizumab Treatment Intervals for Adults with Well-Controlled Chronic Spontaneous Urticaria

    Not recruiting

    3 1 1 1
    Investigated diseases:
    Investigated drugs:
    Denmark

Glossary

  • Omalizumab: A monoclonal antibody medication that targets and neutralizes immunoglobulin E (IgE), used to treat certain allergic and inflammatory conditions.
  • Chronic Spontaneous Urticaria (CSU): A condition characterized by the recurring appearance of hives (urticaria) for 6 weeks or more, often with unknown cause.
  • Immunoglobulin E (IgE): An antibody that plays a crucial role in allergic reactions and is the target of omalizumab therapy.
  • Allergen Immunotherapy: A treatment method that involves exposing patients to gradually increasing amounts of an allergen to reduce their sensitivity and allergic reactions.
  • Asthma Exacerbation: A worsening of asthma symptoms that may require additional treatment or hospitalization.
  • Urticaria Activity Score (UAS7): A tool used to measure the severity of chronic urticaria symptoms over a 7-day period.
  • Subcutaneous Injection: An injection administered into the layer of tissue between the skin and muscle.
  • Monoclonal Antibody: A type of protein made in the laboratory that can bind to specific substances in the body, used in the treatment of various diseases.
  • Placebo: An inactive substance or treatment used in clinical trials as a control to compare against the effects of the investigational drug.
  • Pharmacokinetics: The study of how a drug is absorbed, distributed, metabolized, and eliminated by the body.
  • Pharmacodynamics: The study of the biochemical and physiological effects of drugs on the body and the mechanisms of their actions.

References

  1. https://clinicaltrials.gov/study/NCT00208234
  2. https://clinicaltrials.gov/study/NCT00329381
  3. https://clinicaltrials.gov/study/NCT02550106
  4. https://clinicaltrials.gov/study/NCT01599637
  5. https://clinicaltrials.gov/study/NCT00546143
  6. https://clinicaltrials.gov/study/NCT05157087
  7. https://clinicaltrials.gov/study/NCT01701583
  8. https://clinicaltrials.gov/study/NCT02266355